{"success":true,"data":{"pressRelease":{"id":"46389","rtpr_id":"nPnb9vt2Pa","ticker":"RNAZ","exchange":"NASDAQ","all_tickers":["RNAZ"],"title":"TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer","author":"PR Newswire","published_at":"2026-05-27T12:04:00.048Z","article_body":"TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer\n\nPR Newswire\n\nBOSTON, May 27, 2026\n\nBOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:\nRNAZ), a clinical stage company pioneering immuno-oncology and RNA for the\ntreatment of high risk and advanced cancer, today announced the initiation of\nits Phase 2a clinical trial. The study is to evaluate TransCode's lead\ntherapeutic candidate, TTX‑MC138, in patients with circulating tumor DNA\n(ctDNA) positive colorectal cancer following curative‑intent therapy. The\ntrial is being conducted in collaboration with Quantum Leap Healthcare\nCollaborative (QLHC), sponsor of the PRE‑I‑SPY clinical trial platform.\nThe trial builds on growing clinical and scientific momentum\nsupporting ctDNA‑guided strategies targeting minimal residual disease (MRD)\nin colorectal cancer.\n\nThe Phase 2a clinical trial is expected to enroll up to 45 patients with\ncolorectal cancer who have completed standard curative-intent therapy and have\nno radiographic evidence of disease, but remain or become ctDNA-positive,\nindicating the presence of minimal residual disease.\n\nPrincipal investigators are Dr. Emil Lou of the University of Minnesota and\nDr. Zhaohui Jin of the Mayo Clinic Comprehensive Cancer Center. The trial is\nchaired by Dr. Paula Pohlmann of the MD Anderson Cancer Center.\n\nThe trial leverages clinical sites currently participating and actively\nrecruiting in QLHC's PRE‑I‑SPY platform trial. Several of those clinical\nsites are part of the National Comprehensive Cancer Network (NCCN). Those\ncenters have considerable expertise and are at the forefront defining\nstandard-of-care practices for the treatment of cancer.\n\nIt is anticipated that the trial will produce new data about the importance of\nctDNA testing and the role of TTX-MC138 in reducing the risk of cancer\nrecurrence in this at-risk patient population. The trial has been submitted to\nthe U.S. Food and Drug Administration and received Institutional Review Board\napproval, enabling site activation and commencement of patient enrollment.\n\nThis clinical trial aims to evaluate the biological and clinical activity of\nTTX-MC138 in the minimal residual disease setting where therapeutic\nintervention may have the greatest opportunity to improve long-term outcomes.\nctDNA testing is becoming increasingly important in oncology, particularly in\ncolorectal cancer, because it provides a highly sensitive, real-time measure\nof residual disease and information about tumor biology that traditional\nmethods often fail to detect. This approach has recently been successfully\nemployed in the treatment of patients with muscle invasive bladder cancer.\n\n\"TTX-MC138's safety profile, coupled with the durability of its anti-tumor\neffects, observed in TransCode's Phase 1a clinical trial is particularly\nencouraging. These findings are consistent with the drug's mechanism of action\nand provide a basis for a more rigorous efficacy evaluation. This positions\nTransCode and its collaborators to potentially intervene earlier in a\npatient's disease, and may in the future offer a new therapeutic option for\npatients at risk of developing metastatic disease\" noted Daniel Vlock, MD,\nTransCode's Consulting Clinician.\n\nAbout TTX-MC138\n\nTTX-MC138 is a first-in-class therapeutic candidate designed to inhibit\nmicroRNA-10b, or miR-10b, a microRNA widely believed to be critical to the\nemergence and progression of many metastatic cancers. TransCode's Phase 1a\nfirst-in-human clinical trial achieved its primary safety endpoint and\nestablished a recommended Phase 2 dose, as announced at ESMO 2025.\n\nAbout TransCode Therapeutics\n\nTransCode Therapeutics is a clinical stage company pioneering immuno-oncology\nand RNA therapeutic treatments for high risk and advanced cancers. The\ncompany's lead therapeutic candidate, TTX-MC138, is focused on treating\nmetastatic tumors that overexpress microRNA-10b, a unique, well-documented\nbiomarker of metastasis. In addition, TransCode has a portfolio of other\nfirst-in-class therapeutic candidates designed to mobilize the immune system\nto recognize and destroy cancer cells. For more information, visit\nwww.transcodetherapeutics.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4697201-1&h=560222123&u=https%3A%2F%2Fwww.transcodetherapeutics.com&a=www.transcodetherapeutics.com)\n.\n\nAbout the I-SPY TRIALs\n\nThe I-SPY (\"Investigation of Serial studies to Predict Your Therapeutic\nResponse with Imaging And moLecular analysis\") Trials were designed to rapidly\nscreen promising experimental treatments and identify those most effective for\nbiologically defined patient subgroups. The trials represent a unique\ncollaboration among the U.S. Food and Drug Administration, industry partners,\npatient advocates, philanthropic sponsors, and clinicians across leading U.S.\ncancer research centers. Quantum Leap Healthcare Collaborative is the trial\nsponsor and oversees all operational, regulatory, and data-integration\nactivities. The PRE-ISPY platform extends I-SPY into early feasibility testing\nto accelerate biologically targeted therapies into the curative setting. For\nmore information, visit www.ispytrials.org\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4697201-1&h=1706523338&u=http%3A%2F%2Fwww.ispytrials.org%2F&a=www.ispytrials.org)\n.\n\nAbout Quantum Leap Healthcare Collaborative\n\nQuantum Leap Healthcare Collaborative is a 501(c)(3) nonprofit organization\nfounded in 2005 by UCSF researchers and Silicon Valley innovators. Its mission\nis to integrate clinical care with research, advance high-impact platform\ntrials, and improve patient outcomes through adaptive learning systems,\nenhanced data infrastructure, and widespread trial accessibility. Quantum Leap\nsponsors and manages the I-SPY Trial programs. For additional information,\nvisit www.quantumleaphealth.org\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4697201-1&h=4281739364&u=http%3A%2F%2Fwww.quantumleaphealth.org%2F&a=www.quantumleaphealth.org)\n.\n\nForward-Looking Statements\n\nThis release contains \"forward-looking statements\" within the meaning of the\nPrivate Securities Litigation Reform Act of 1995, including, without\nlimitation, statements concerning the timing, conduct and results of\nTransCode's collaborations, TransCode's Phase 1a clinical trial, and\nTransCode's planned Phase 2a clinical trial, statements about microRNAs and\ntheir involvement in cancer, and statements concerning the therapeutic\npotential of TransCode's TTX-MC138 and other therapeutic candidates. Any\nforward-looking statements in this press release are based on management's\ncurrent expectations of future events and are subject to a number of risks and\nuncertainties that could cause actual results to differ materially and\nadversely from those set forth in or implied by such forward-looking\nstatements. These risks and uncertainties include, but are not limited to: the\nrisks associated with drug discovery and development; the risk that the\nresults of clinical trials will not be consistent with TransCode's preclinical\nstudies or expectations or with results from previous clinical trials; risks\nassociated with the conduct of clinical trials; risks associated with\nTransCode's financial condition and its need to obtain additional funding to\nsupport its business activities, including TransCode's ability to continue as\na going concern; risks associated with the timing and outcome of TransCode's\nplanned regulatory submissions; risks associated with obtaining, maintaining\nand protecting intellectual property; risks associated with TransCode's\nability to enforce its patents against infringers and defend its patent\nportfolio against challenges from third parties; risks of competition from\nother companies developing products for similar uses; risks associated with\nTransCode's dependence on third parties; and risks associated with\ngeopolitical events and pandemics, including the COVID-19 coronavirus and\nmilitary actions. For a discussion of these and other risks and uncertainties,\nand other important factors, any of which could cause TransCode's actual\nresults to differ from those contained in or implied by the forward-looking\nstatements, see the section entitled \"Risk Factors\" in TransCode's Annual\nReport on Form 10-K for the year ended December 31, 2025, as well as\ndiscussions of potential risks, uncertainties and other important factors in\nany subsequent TransCode filings with the Securities and Exchange Commission.\nAll information in this press release is as of the date of this release;\nTransCode undertakes no duty to update this information unless required by\nlaw.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/transcode-therapeutics-initiates-phase-2a-clinical-trial-with-ttx-mc138-in-patients-with-ctdna-positive-colorectal-cancer-302782666.html\n(https://www.prnewswire.com/news-releases/transcode-therapeutics-initiates-phase-2a-clinical-trial-with-ttx-mc138-in-patients-with-ctdna-positive-colorectal-cancer-302782666.html)\n\nSOURCE TransCode Therapeutics, Inc.\n\n\n\nCONTACT; For more information and partnering opportunities, please contact: TransCode Therapeutics, Inc., Tania Montgomery, VP of Business Development, tania.montgomery@transcodetherapeutics.com; Quantum Leap Healthcare Collaborative, Paul Henderson, PhD, Senior Director of Collaborations, p.henderson@qlhc.org\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1773301/TransCode_Therapeutics_Inc.jpg?id=OA2642723\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnb9vt2Pa","title":"TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer","author":"PR Newswire","ticker":"RNAZ","created":"2026-05-27T12:04:00.048Z","tickers":["RNAZ"],"exchange":"NASDAQ","article_body":"TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer\n\nPR Newswire\n\nBOSTON, May 27, 2026\n\nBOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:\nRNAZ), a clinical stage company pioneering immuno-oncology and RNA for the\ntreatment of high risk and advanced cancer, today announced the initiation of\nits Phase 2a clinical trial. The study is to evaluate TransCode's lead\ntherapeutic candidate, TTX‑MC138, in patients with circulating tumor DNA\n(ctDNA) positive colorectal cancer following curative‑intent therapy. The\ntrial is being conducted in collaboration with Quantum Leap Healthcare\nCollaborative (QLHC), sponsor of the PRE‑I‑SPY clinical trial platform.\nThe trial builds on growing clinical and scientific momentum\nsupporting ctDNA‑guided strategies targeting minimal residual disease (MRD)\nin colorectal cancer.\n\nThe Phase 2a clinical trial is expected to enroll up to 45 patients with\ncolorectal cancer who have completed standard curative-intent therapy and have\nno radiographic evidence of disease, but remain or become ctDNA-positive,\nindicating the presence of minimal residual disease.\n\nPrincipal investigators are Dr. Emil Lou of the University of Minnesota and\nDr. Zhaohui Jin of the Mayo Clinic Comprehensive Cancer Center. The trial is\nchaired by Dr. Paula Pohlmann of the MD Anderson Cancer Center.\n\nThe trial leverages clinical sites currently participating and actively\nrecruiting in QLHC's PRE‑I‑SPY platform trial. Several of those clinical\nsites are part of the National Comprehensive Cancer Network (NCCN). Those\ncenters have considerable expertise and are at the forefront defining\nstandard-of-care practices for the treatment of cancer.\n\nIt is anticipated that the trial will produce new data about the importance of\nctDNA testing and the role of TTX-MC138 in reducing the risk of cancer\nrecurrence in this at-risk patient population. The trial has been submitted to\nthe U.S. Food and Drug Administration and received Institutional Review Board\napproval, enabling site activation and commencement of patient enrollment.\n\nThis clinical trial aims to evaluate the biological and clinical activity of\nTTX-MC138 in the minimal residual disease setting where therapeutic\nintervention may have the greatest opportunity to improve long-term outcomes.\nctDNA testing is becoming increasingly important in oncology, particularly in\ncolorectal cancer, because it provides a highly sensitive, real-time measure\nof residual disease and information about tumor biology that traditional\nmethods often fail to detect. This approach has recently been successfully\nemployed in the treatment of patients with muscle invasive bladder cancer.\n\n\"TTX-MC138's safety profile, coupled with the durability of its anti-tumor\neffects, observed in TransCode's Phase 1a clinical trial is particularly\nencouraging. These findings are consistent with the drug's mechanism of action\nand provide a basis for a more rigorous efficacy evaluation. This positions\nTransCode and its collaborators to potentially intervene earlier in a\npatient's disease, and may in the future offer a new therapeutic option for\npatients at risk of developing metastatic disease\" noted Daniel Vlock, MD,\nTransCode's Consulting Clinician.\n\nAbout TTX-MC138\n\nTTX-MC138 is a first-in-class therapeutic candidate designed to inhibit\nmicroRNA-10b, or miR-10b, a microRNA widely believed to be critical to the\nemergence and progression of many metastatic cancers. TransCode's Phase 1a\nfirst-in-human clinical trial achieved its primary safety endpoint and\nestablished a recommended Phase 2 dose, as announced at ESMO 2025.\n\nAbout TransCode Therapeutics\n\nTransCode Therapeutics is a clinical stage company pioneering immuno-oncology\nand RNA therapeutic treatments for high risk and advanced cancers. The\ncompany's lead therapeutic candidate, TTX-MC138, is focused on treating\nmetastatic tumors that overexpress microRNA-10b, a unique, well-documented\nbiomarker of metastasis. In addition, TransCode has a portfolio of other\nfirst-in-class therapeutic candidates designed to mobilize the immune system\nto recognize and destroy cancer cells. For more information, visit\nwww.transcodetherapeutics.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4697201-1&h=560222123&u=https%3A%2F%2Fwww.transcodetherapeutics.com&a=www.transcodetherapeutics.com)\n.\n\nAbout the I-SPY TRIALs\n\nThe I-SPY (\"Investigation of Serial studies to Predict Your Therapeutic\nResponse with Imaging And moLecular analysis\") Trials were designed to rapidly\nscreen promising experimental treatments and identify those most effective for\nbiologically defined patient subgroups. The trials represent a unique\ncollaboration among the U.S. Food and Drug Administration, industry partners,\npatient advocates, philanthropic sponsors, and clinicians across leading U.S.\ncancer research centers. Quantum Leap Healthcare Collaborative is the trial\nsponsor and oversees all operational, regulatory, and data-integration\nactivities. The PRE-ISPY platform extends I-SPY into early feasibility testing\nto accelerate biologically targeted therapies into the curative setting. For\nmore information, visit www.ispytrials.org\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4697201-1&h=1706523338&u=http%3A%2F%2Fwww.ispytrials.org%2F&a=www.ispytrials.org)\n.\n\nAbout Quantum Leap Healthcare Collaborative\n\nQuantum Leap Healthcare Collaborative is a 501(c)(3) nonprofit organization\nfounded in 2005 by UCSF researchers and Silicon Valley innovators. Its mission\nis to integrate clinical care with research, advance high-impact platform\ntrials, and improve patient outcomes through adaptive learning systems,\nenhanced data infrastructure, and widespread trial accessibility. Quantum Leap\nsponsors and manages the I-SPY Trial programs. For additional information,\nvisit www.quantumleaphealth.org\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4697201-1&h=4281739364&u=http%3A%2F%2Fwww.quantumleaphealth.org%2F&a=www.quantumleaphealth.org)\n.\n\nForward-Looking Statements\n\nThis release contains \"forward-looking statements\" within the meaning of the\nPrivate Securities Litigation Reform Act of 1995, including, without\nlimitation, statements concerning the timing, conduct and results of\nTransCode's collaborations, TransCode's Phase 1a clinical trial, and\nTransCode's planned Phase 2a clinical trial, statements about microRNAs and\ntheir involvement in cancer, and statements concerning the therapeutic\npotential of TransCode's TTX-MC138 and other therapeutic candidates. Any\nforward-looking statements in this press release are based on management's\ncurrent expectations of future events and are subject to a number of risks and\nuncertainties that could cause actual results to differ materially and\nadversely from those set forth in or implied by such forward-looking\nstatements. These risks and uncertainties include, but are not limited to: the\nrisks associated with drug discovery and development; the risk that the\nresults of clinical trials will not be consistent with TransCode's preclinical\nstudies or expectations or with results from previous clinical trials; risks\nassociated with the conduct of clinical trials; risks associated with\nTransCode's financial condition and its need to obtain additional funding to\nsupport its business activities, including TransCode's ability to continue as\na going concern; risks associated with the timing and outcome of TransCode's\nplanned regulatory submissions; risks associated with obtaining, maintaining\nand protecting intellectual property; risks associated with TransCode's\nability to enforce its patents against infringers and defend its patent\nportfolio against challenges from third parties; risks of competition from\nother companies developing products for similar uses; risks associated with\nTransCode's dependence on third parties; and risks associated with\ngeopolitical events and pandemics, including the COVID-19 coronavirus and\nmilitary actions. For a discussion of these and other risks and uncertainties,\nand other important factors, any of which could cause TransCode's actual\nresults to differ from those contained in or implied by the forward-looking\nstatements, see the section entitled \"Risk Factors\" in TransCode's Annual\nReport on Form 10-K for the year ended December 31, 2025, as well as\ndiscussions of potential risks, uncertainties and other important factors in\nany subsequent TransCode filings with the Securities and Exchange Commission.\nAll information in this press release is as of the date of this release;\nTransCode undertakes no duty to update this information unless required by\nlaw.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/transcode-therapeutics-initiates-phase-2a-clinical-trial-with-ttx-mc138-in-patients-with-ctdna-positive-colorectal-cancer-302782666.html\n(https://www.prnewswire.com/news-releases/transcode-therapeutics-initiates-phase-2a-clinical-trial-with-ttx-mc138-in-patients-with-ctdna-positive-colorectal-cancer-302782666.html)\n\nSOURCE TransCode Therapeutics, Inc.\n\n\n\nCONTACT; For more information and partnering opportunities, please contact: TransCode Therapeutics, Inc., Tania Montgomery, VP of Business Development, tania.montgomery@transcodetherapeutics.com; Quantum Leap Healthcare Collaborative, Paul Henderson, PhD, Senior Director of Collaborations, p.henderson@qlhc.org\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1773301/TransCode_Therapeutics_Inc.jpg?id=OA2642723\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-27T12:04:00.084974037Z","server_sent_at_ms":1779883440084},"received_at":"2026-05-27T12:04:00.142Z","source_url":"https://www.prnewswire.com/news-releases/transcode-therapeutics-initiates-phase-2a-clinical-trial-with-ttx-mc138-in-patients-with-ctdna-positive-colorectal-cancer-302782666.html"},"analysis":{"id":"35823","press_release_id":"46389","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"TransCode Therapeutics has initiated a Phase 2a clinical trial for its lead candidate TTX-MC138 in patients with ctDNA-positive colorectal cancer following curative-intent therapy.\n\nThe study, conducted in collaboration with Quantum Leap Healthcare Collaborative (QLHC) via the PRE-I-SPY platform, aims to enroll up to 45 patients with minimal residual disease.\n\nPrincipal investigators include Dr. Emil Lou and Dr. Zhaohui Jin, with Dr. Paula Pohlmann chairing the trial. The move leverages the safety profile established in the prior Phase 1a trial to evaluate efficacy in reducing recurrence risk.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"TransCode advances lead asset TTX-MC138 into Phase 2a via prestigious QLHC PRE-I-SPY platform, targeting ctDNA+ colorectal cancer patients."},"keyFigures":{"drugName":"TTX-MC138","phaseOfTrial":"Phase 2a","customDimensions":{"enrollment_target":45}},"quotedText":"TTX-MC138's safety profile, coupled with the durability of its anti-tumor effects, observed in TransCode's Phase 1a clinical trial is particularly encouraging.","namedEntities":{"people":[{"name":"Dr. Emil Lou","role":"Principal Investigator"},{"name":"Dr. Zhaohui Jin","role":"Principal Investigator"},{"name":"Dr. Paula Pohlmann","role":"Trial Chair"},{"name":"Daniel Vlock","role":"Consulting Clinician"},{"name":"Tania Montgomery","role":"VP of Business Development"},{"name":"Paul Henderson","role":"Senior Director of Collaborations"}],"products":["TTX-MC138"],"companies":[{"name":"TransCode Therapeutics, Inc.","ticker":"RNAZ","relationship":"filer"},{"name":"Quantum Leap Healthcare Collaborative","relationship":"partner/sponsor"},{"name":"University of Minnesota","relationship":"clinical site"},{"name":"Mayo Clinic Comprehensive Cancer Center","relationship":"clinical site"},{"name":"MD Anderson Cancer Center","relationship":"clinical site"},{"name":"National Comprehensive Cancer Network","relationship":"network"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Initiation of a Phase 2a trial for the lead asset TTX-MC138 in a specific biomarker-defined population (ctDNA+ colorectal cancer). This is a standard but positive de-risking step for a clinical-stage biotech, leveraging the prestigious PRE-I-SPY platform. It is not a binary approval event, but confirms progression from Phase 1a."},"tickerRelevance":{"others":[],"primary":"RNAZ"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"phase_2_initiation","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"clinical_trial","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":3,"narrative":"TransCode Therapeutics has initiated a Phase 2a clinical trial for its lead candidate TTX-MC138 in patients with ctDNA-positive colorectal cancer following curative-intent therapy.\n\nThe study, conducted in collaboration with Quantum Leap Healthcare Collaborative (QLHC) via the PRE-I-SPY platform, aims to enroll up to 45 patients with minimal residual disease.\n\nPrincipal investigators include Dr. Emil Lou and Dr. Zhaohui Jin, with Dr. Paula Pohlmann chairing the trial. The move leverages the safety profile established in the prior Phase 1a trial to evaluate efficacy in reducing recurrence risk.","key_figures":{"drugName":"TTX-MC138","phaseOfTrial":"Phase 2a","customDimensions":{"enrollment_target":45}},"named_entities":{"people":[{"name":"Dr. Emil Lou","role":"Principal Investigator"},{"name":"Dr. Zhaohui Jin","role":"Principal Investigator"},{"name":"Dr. Paula Pohlmann","role":"Trial Chair"},{"name":"Daniel Vlock","role":"Consulting Clinician"},{"name":"Tania Montgomery","role":"VP of Business Development"},{"name":"Paul Henderson","role":"Senior Director of Collaborations"}],"products":["TTX-MC138"],"companies":[{"name":"TransCode Therapeutics, Inc.","ticker":"RNAZ","relationship":"filer"},{"name":"Quantum Leap Healthcare Collaborative","relationship":"partner/sponsor"},{"name":"University of Minnesota","relationship":"clinical site"},{"name":"Mayo Clinic Comprehensive Cancer Center","relationship":"clinical site"},{"name":"MD Anderson Cancer Center","relationship":"clinical site"},{"name":"National Comprehensive Cancer Network","relationship":"network"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-27T12:10:24.456Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"phase_2_initiation","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":24002,"modelName":"george-droid-qwen-72b"}}